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Abstract
Background: The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma
(MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the
mechanism of cytotoxicity is not well understood.
Methodology/Principal Findings: We investigated the differential phosphoproteome upon proteasome inhibition by using
stable isotope labeling by amino acids in cell culture (SILAC) in combination with phosphoprotein enrichment and LC-MS/
MS analysis. In total 233 phosphoproteins were identified and 72 phosphoproteins showed a 1.5-fold or greater change
upon bortezomib treatment. The phosphoproteins with expression alterations encompass all major protein classes,
including a large number of nucleic acid binding proteins. Site-specific phosphopeptide quantitation revealed that Ser38
phosphorylation on stathmin increased upon bortezomib treatment, suggesting new mechanisms associated to
bortezomib-induced apoptosis in MM cells. Further studies demonstrated that stathmin phosphorylation profile was
modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr
residues participated in the cellular response induced by bortezomib.
Conclusions/Significance: Our systematic profiling of phosphorylation changes in response to bortezomib treatment not
only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified
previously uncharacterized signaling proteins in myeloma cells.
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Introduction
The ubiquitin-proteasome pathway is responsible for proteolysis
of eukaryotic cellular proteins related to cell cycle regulation, cell
survival, and apoptosis [1]. Inhibition of proteasome activity is a
novel therapeutic strategy against cancer cells. Bortezomib
(formerly known as PS-341), a cell-permeable boronic acid
dipeptide, is a specific inhibitor of the proteasome pathway [2]
and received Food and Drug Administration (FDA) approval for
the treatment of MM and mantle cell lymphoma [3].
Bortezomib has been reported to trigger pleiotropic signaling
pathways in MM cells, including: (a) stabilizing cytoplasmic IkB
and blocking NFkB nuclear translocation [4]; (b) activation of
stress response proteins such as heat shock proteins Hsp27, Hsp70,
and Hsp90 [5]; (c) up-regulation of c-jun NH2-terminal kinase [6];
(d) induction of intrinsic cell death pathway [7]; (e) activation of
extrinsic apoptotic signaling through Bid and caspase-8 cleavage
[8]; (f) impairment of DNA repair machinery via inactivation of
DNA-dependent protein kinase [9]; (g) down-regulation of
mitogen-activated protein kinase and phosphatidylinositol 3-
kinase/Akt signaling pathways [10]; and (h) down-regulation of
the p44/42 MAPK signaling cascade [11]. All these signaling
events may collectively contribute towards the overall anti-MM
activity of bortezomib. However, the exact number and identity of
cellular signaling events involved in proteasome inhibition and the
mechanisms underlying the associated apoptotic response in MM
cells remain to be elucidated.
Elucidation of cellular signaling networks requires methodolo-
gies for large-scale quantitative phosphoproteomic analysis that
can reveal dynamic system-wide changes in protein phosphoryla-
tion. Recent technological advances in mass spectrometry-based
proteomics have enabled us to make a large-scale identification of
signaling molecules through the enrichment of phosphorylated
proteins or peptides [12,13]. One of the most widely used and well
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stable-isotope labelling by amino acids in cell culture (SILAC).
Although introduced relatively recently, SILAC has been used
extensively in the proteomics community [14]. With SILAC, the
entire proteome of a given cell population is metabolically labeled
by heavy, non-radioactive isotopic variants of amino acids, thus
making it distinguishable by MS analysis [15,16]. Thereafter, two
or more distinctly SILAC-labeled cell populations can be mixed
and analyzed in one MS experiment, allowing accurate quanti-
zation of proteins from the different cellular states. By coupling
with a phosphoprotein or phosphopeptide enrichment method,
such as titanium dioxide (TiO2) [17], strong cation exchange
(SCX) [18], or the two in combination [19], SILAC has been
widely applied to profile dynamic phosphorylation changes in
signal transduction [20,21].
In this study, we investigated the differential MM phosphopro-
teome upon proteasome inhibition by using SILAC in combina-
tion with phosphoprotein enrichment and LC-MS/MS analysis.
Many potential novel signaling proteins and associated signaling
pathways were confidently identified. Our further functional
results indicated that perturbations in stathmin phosphorylation
play a significant functional role in mediating apoptosis in MM
cells exposed to bortezomib and the bortezomib-induced changes
in the MT stabilization can be attributed to the bortezomib-
induced phosphorylation of stathmin. By correlating the phos-
phoproteomic data with functional studies, the current results
provided novel insights into the mechanisms of bortezomib actions
in MM cells.
Results
Quantitative Phosphoproteomic Analysis of Proteasome
Inhibition in Myeloma Cells
To obtain a global view of the changes of protein phosphor-
ylation in bortezomib-treated myeloma cells, we compared the
phosphoproteome of U266 cells treated with or without bortezo-
mib. The workflow is outlined in Figure 1. Cells in normal
medium (light culture) were treated with bortezomib, and cells
grown in medium containing stable isotopes (heavy culture) were
treated with vehicle. These two populations of cells were lysed,
mixed at a 1:1 ratio, and subjected to TiO2 purifications followed
by LC-MS/MS analysis. After LC-MS/MS analysis on the
enriched phosphopeptides, all MS/MS spectra were searched,
respectively, against the forward and reversed human protein
sequence databases to estimate rates of false-positive matches.
Search results were filtered based on peptide score of MASCOT
and PTM score. In total 1024 phosphopeptides (redundant) from
the target database passed our criteria, allowing 14 decoy matches.
The phosphopeptide false-positive rate was therefore estimated to
be 1.4%. Multiple filtering criteria were established to validate
search results. For each of the phosphorylated peptides identified
in this work, peptide sequences were manually confirmed. After
validation we identified 418 unique phosphorylation sites from 244
unique phosphopeptides corresponding to 233 protein groups.
This entire dataset is provided as Table S1 in which hyperlinks are
built up to view all the MS/MS spectra. Using the PTM score, we
could localize the phosphor groups with high confidence (Class I
phosphorylation sites) in 197 cases (Table S1), indicating that the
phosphorylation sites detected by current strategy are of high
confidence. Figure 2A shows a representative MS/MS spectrum
for a phosphosite-containing peptide in the detection, and all other
MS/MS spectra are available via the hyperlinks in the Table S1.
To quantify the phosphorylation change for each phosphopep-
tide, we used the MSQuant software to calculate area ratio,
defined as the ratio of the ‘‘heavy’’ peak area over the ‘‘light’’ peak
area in the chromatogram (Fig. 2B). All together, we have
achieved quantification of 259 unique phosphorylation sites from
154 unique phosphopeptides corresponding to 132 protein groups.
Based on a predefined threshold of 1.5-fold change, 131
phosphosites from 75 unique phosphopeptides corresponding to
72 proteins showed a 1.5-fold or greater change as listed in Table
S2. In other words, 31% of the total phosphosites detected showed
significant alteration after bortezomib treatment, suggesting that
dysregulated phosphorylation may play an important role in
bortezomib-induced apoptosis.
Validation of Differential Expressed Phosphoproteins
To further confirm the results from the quantitative phospho-
proteome analysis, we chose stathmin for Western blotting
verification using an anti-phospho-Ser38 stathmin antibody. As
shown in Figure 2C, SILAC results were very much consistent
with Western blotting analysis for this protein. Upon bortezomib
treatment, phosphorylation of stathmin at Ser38 increased,
whereas steady-state stathmin remained almost unchanged in
Western blotting verification.
Functional Categories and Biological Interaction
Networking of Bortezomib-Regulated Phosphoproteins
To better characterize bortezomib-regulated phosphoproteins,
we classified all the differentially expressed phosphoproteins
(DEPPs) into 23 functional categories according to the PANTHER
system. These proteins are implicated in a broad range of cellular
activities (Fig. 3A). Next to the unclassified proteins (17%), proteins
involved in nucleic acid binding account for the second largest
portion (14%). There are also a significant number of proteins
Figure 1. Schematic diagram of the experimental procedures.
The application of SILAC in differential phosphoproteomic profiling of
myeloma cells U266 treated by bortezomib.
doi:10.1371/journal.pone.0013095.g001
Phosphoproteomics of Myeloma
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e13095involved in receptor (10%), regulatory molecule (6%), and kinase
(5%). Previous studies indicated that bortezomib exerts its
anticancer function by inhibiting protein degradation in cancer
cells [22]. In this connection, many bortezomib-regulated
phosphoproteins found in current study were nucleic acid binding
(14%) and transcription factors (4%), as shown in Figure 3A.
These data suggest that the cancer-inhibitory effect of bortezomib
may also rely on its regulatory role in mRNA transcription.
Figure 2. Identification and quantization of Ser38 phosphorylation of stathmin. (A) Representative MS/MS spectrum of phosphopeptide
ESVPEFPLpSPPK. (B) Representative chromatogram of ESVPEFPLpSPPK. Ion chromatograms of [
12C6] lysine- and [
13C6] lysine-containing peptides
identified by MS/MS were extracted from the series of MS scans by using MSQuant. (C) Western blot analyses using specific antibodies showed that
phosphorylation of stathmin at Ser38 was increased, whereas steady-state stathmin remained almost unchanged upon bortezomib treatment.
doi:10.1371/journal.pone.0013095.g002
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phosphoproteins in MM cells. It lacks the biochemical context.
To create significance out of otherwise static proteomic data, we
constructed an interaction networking of the DEPPs (Fig. 3B). The
DEPPs were linked by various evidences based on neighborhood
analysis, experimental results or text-mining. These relationships
are color coded, and the legends are provided next to the map.
This does not mean that all the interactions took place within a
single spatial and temporal situation, but it enables the
identification of central nodes in these DEPPs. Notably, stathmin
was a hub in this network, suggesting that stathmin may play an
important role in mediating bortezomib-induced apoptosis in MM
cells. Some proteins remained orphans because there is insufficient
information in the database to link them to other proteins in the
network.
Bioinformatics Analysis
To further investigate the reliability of the results, PhosphoSite
(http://www.Phosphosite.org) was used to distinguish known
phosphorylation sites from novel phosphorylation sites. Among
the identified 418 phosphorylated sites, 51% were also reported by
others previously (for details, see Table S3). In other words, many
of the phosphorylation sites were also determined by researchers
with other cancer cells, further demonstrating that the phosphor-
ylation sites detected by current strategy are reliable.
To predict the kinase substrate relationships from the dataset,
the computer algorithm SCANSITE was used. SCANSITE makes
use of peptide library phosphorylation data to predict substrates
recognized by specific kinases. Tables S4 & S5 show the results of
phosphopeptides that were identified in this study and were
predicted to be associated with a kinase binding motif by
SCANSITE at the different stringency levels. It was found that
most of the phosphorylation sites determined in this study were
phosphorylated by acidophilic serine/threonine kinase and
proline-dependent serine/threonine kinase. Notably, we found
fifteen sites that can be phosphorylated by the Casein Kinase 2
(CK2). CK2 is a constitutively active protein kinase implicated in
cellular transformation and the development of tumorigenesis
[23]. Aberrantly active in MM cells, CK2 controls the cell survival
[24]. Our SCANSITE analysis suggests that CK2 may play an
important role in bortezomib-induced apoptosis and may
represent a potential target in MM therapy.
Regulation of Stathmin Phosphorylation by Bortezomib
SILAC phosphoproteomic analyses and Western blotting
revealed an increase of phosphorylation of stathmin at Ser38
and the unchanged steady-state stathmin in U266 cells upon
proteasome inhibition (Fig. 2). It has been reported that the
functional alteration of stathmin resulting from specific phosphor-
ylation events may be involved in the process of apoptosis induced
by proteasome inhibitors in proliferating cells [25]. To elucidate
the differential phosphorylation of stathmin isoforms, Western
blotting was performed to analyze the phosphorylation pattern of
stathmin in bortezomib-treated U266 cells using stathmin
antibody and specific phospho-antibodies against three known
phospho-sites (Ser16, Ser25, Ser38) [26]. As shown in Figure 4A,
in accordance with SILAC results, phosphorylation of stathmin at
Ser38 was increased whereas steady-state stathmin remained
unchanged. Furthermore, phosphorylation of stathmin at Ser16
was increased whereas Ser25 was decreased after bortezomib
treatment (Fig. 4A).
It has also been reported that Ser16 is a target for calmodulin-
dependent protein kinases (CamKII), Ser25 is specifically
phosphorylated by mitogen-activated protein (MAP) kinase, and
Ser38 is a target for cycline-dependent kinase-2 (CDK2) [26]. To
test the activation status of upstream kinases catalyzing the
incorporation of phosphoryl groups to each of these residues,
specific antibodies against active forms of CaMKII, MAPK and
CDK2 (responsible for the stathmin phosphorylation on Ser16,
Ser25 and Ser38, respectively) were used. In accordance with the
increase in p-Ser16 and p-Ser38 of stathmin in bortezomib-treated
cells, a parallel activation of CamKII and CDK2 was detected
after bortezomib treatment (Fig. 4B). At the same time, the
decrease in phosphorylation levels of Ser25 was correlated with the
inactivation of MAPK, a critical kinase for cell survival.
Hence, these results suggest that the regulation of the
phosphorylation profile of stathmin at the level of residues
Ser16, Ser25, and Ser38 may participate in the response of
myeloma cells to proteasome inhibitors, and that stathmin is a
target for multiple protein kinases, which are regulated by multiple
signal transduction cascades.
Mutation of Stathmin Phosphorylation Site Decreases
Sensitivity to Bortezomib and Influences Tubulin
Polymerization
The functional significance of stathmin phosphorylation in the
response of MM cells to bortezomib was then examined more
rigorously. To this end, stable U266 cell clones overexpressing the
Figure 3. Bioinformatic analysis of identified DEPPs. (A) Pie chart representations of the distribution of identified DEPPs according to their
molecular functions. Categorizations were based on information provided by the online resource PANTHER classification system. (B) The protein
interaction network of the identified DEPPs. The network was mapped using the STRING system (http://string.embl.de/) based on evidence with
different types. Different line colors represent the types of evidence for the associations, which are shown in the legend.
doi:10.1371/journal.pone.0013095.g003
Figure 4. Phosphorylation pattern of stathmin under bortezo-
mib treatment. (A) Upregulation of the phosphorylation at Ser16 and
Ser38 and down-regulation of the phosphorylation at Ser25 were
observed in bortezomib-treated U266 cells. (B) Activation of kinases
targeting these residues (CaMKII, CDK2, and MAPK) was studied by
Western blot using specific antibodies. Equal protein loading was
assessed with actin.
doi:10.1371/journal.pone.0013095.g004
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S25A and U266-S38A) were generated using His-tagged con-
structs. Figure 5A shows the expression of His-tagged target
proteins as well as stathmin expression in these cells. The complete
methods and characterization in terms of proliferation, cell cycle,
colony-forming efficiency (CFE) and apoptotic ratio of these cells
are described in the Supplemental Data S1. We observed that all
these cells had a comparable growth pattern and CFE, similar
proportions of cells in G1, S, and G2 plus M phases and similar
apoptotic ratio (Table S6). However, there were significant
differences between these cells with regard to their sensitivity to
bortezomib treatment. As shown in Figure 5B, cells transfected
with wild-type stathmin (U266-WT) exhibited significant increase
in bortezomib-induced cell death compared with parental cells
(U266). In contrast, cells transfected with mutant stathmin (U266-
S16A, U266-S25A or U266-S38A) were significantly less sensitive
to bortezomib lethality than U266 cells (P,0.05 for U266-S16A
and U266-S38A or P,0.01 for U266-S25A, respectively) (Fig. 5B).
It hasbeen reported that phosphorylation turnsoff the microtubule
destabilizing activity of stathmin [27,28] and that proteasome
inhibitors increase tubulin polymerization and stabilization in
myeloma cells [29]. We thus tested whether bortezomib actually
induced changes in the polymerization status of the MTs in these
cells. Indeed, when these cells were treated with bortezomib for
24 hours, we observed an increase in the amount of tubulin in the
polymerized ‘P’ fraction as compared with untreated cells (Fig. 5C).
T h eb a s e l i n ep r o p o r t i o no fa-tubulin in the polymerized fraction
ranged from ,43% to 52%, while the polymerized proportion
observed after bortezomib treatment was ,60–90% (Table 1).
To investigate whether these bortezomib-induced changes in
the tubulin polymerization were mediated by phosphorylation of
stathmin, we examined the tubulin polymerization in stable U266
clones that overexpressing WT stathmin and the phosphorylation
site-deficient stathmin mutants S16A, S25A and S38A. As shown
in Figure 5C, by comparing with U266 cells, overexpression of
WT stathmin and phosphorylation site-deficient mutants resulted
in a significant decrease in the percent of polymerized tubulin
following treatment with bortezomib (Fig. 5C and Table 1).
Thus, our findings support the notion that bortezomib induces
tubulin polymerization and stabilization through the mediation by
phosphorylation of stathmin and this may be a contribution factor to
the mechanism of proteasome inhibition and toxicity in MM cells.
Figure 5. Mutation of stathmin phosphorylation sites decreases sensitivity to bortezomib and influences tubulin polymerization.
(A) U266 cells were stably transfected with HA-tagged wild type (WT) and mutant (S16A, S25A, S38A) stathmin constructs or its empty vector (NC). (B)
Cells were exposed to 3 nM bortezomib for 24 hr, after which the percentage of apoptotic cells was determined by Annexin V/PI staining and flow
cytometry. Results represent the means (6 SD) for 3 separate experiments performed in triplicate. (*P,0.05 and **P,0.01). (C) Analysis of tubulin
polymerization in U266 or derived cells with or without bortezomib treatment. Lysates from these cells were obtained from cells either treated or not
with bortezomib at the indicated concentration. Lysates were separated into polymerized (P) or soluble (S) fractions and aliquots of equal volume
were separated by SDS-PAGE, the blots probed with anti a-tubulin and the percent of polymerized tubulin calculated for each ‘P’ and ‘S’ pair.
doi:10.1371/journal.pone.0013095.g005
Table 1. Percent of polymerized tubulin in U266 and derived
cells treated with bortezomib.
Cell
% Polymerized tubulin
average ± S.D. p-value
No treatment
3n M
bortezomib p1* p2*
U266 50.563.2 90.569.2 ,0.001 -
U266-NC 49.166.7 83.267.8 0.003 0.075
U266-WT 51.264.6 78.665.5 0.005 0.042
U266-S16A 52.563.9 74.167.6 0.007 0.015
U266-S25A 43.668.9 60.865.1 0.011 0.003
U266-S38A 51.667.7 61.868.5 0.047 0.004
*p1: 3 nM bortezomib treated vs. No treatment.
*p2: U266 derived cells vs. U266 cells with bortezomib treatment.
doi:10.1371/journal.pone.0013095.t001
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Quantitative phosphoproteomic approaches offer great promise
for rapid progress in the analysis of drug targets or mechanism of
action, especially when combined with traditional biochemical
approaches presently used for studying individual proteins [30].
Moreover, the ability to simultaneously measure changes in
phosphorylation state of many proteins in a single experiment can
provide unique information needed for quantitative modeling of
signaling pathways.
In the present study, we used a combined strategy that
comprised phosphoprotein enrichment, SILAC, and LC/MS
analysis to profile the differential phosphoproteome in bortezo-
mib-treated MM cells. A total of 72 phosphoproteins were found
to have a 1.5-fold or greater change upon bortezomib treatment
(Table S2). According to their change pattern, these DEPPs can be
categorized into up- (,0.75) or down- (.1.5) regulated groups
(Table S2). Notably, in comparison with the number of down-
regulated DEPPs, many more proteins are up-regulated in this
process (70 versus 5). This unbalanced pattern has also been
revealed by previous in vitro biochemical studies [22]. Many studies
have demonstrated that bortezomib can trigger pleiotropic
signaling pathways and suppress the proteasomal degradation of
multiple phosphorylated singnaling molecules [8,10,31]. There-
fore, we speculate that the up-regulation of phosporylation of these
DEPPs may constitute one of the mechanisms of bortezomib-
induced apoptosis in MM cells. The PANTHER classification
system also revealed that the DEPPs implicated in a variety of
molecular functions, such as nucleic acid binding, receptor,
regulatory molecule and so on (Fig. 3A), clearly showing that in
addition to targeting proteins involved in apoptotic pathways,
bortezomib also altered multiple signaling pathways to induce its
anti-cancer effects.
In particular, as suggested by protein network analysis (Fig. 3B),
stathmin may play a central role in mediating bortezomib-induced
apoptosis in MM cells. Stathmin (also termed as p19, 19K, p18,
prosolin, and Op18) is a ubiquitous 19 kDa cytosolic phospho-
protein that is highly expressed in a wide variety of cancers,
including a subset of leukemias and breast carcinomas and is a key
regulator in the control of proliferation and cell cycle [32,33].
Stathmin is a phosphorylation responsive regulator of microtubule
(MT) dynamics that increases the catastrophe rate of MTs
(depolymerization or shrinkage phase of individual MTs) in a
dose-dependent manner [34]. Four Ser residues, Ser16, Ser25,
Ser38, and Ser63 in stathmin are subjects for phosphorylation in
intact cells [26].
The regulation of stathmin phosphorylation is complex and, in
all likelihood, multifactorial. For example, phosphorylations at all
four Ser residues fluctuate during the cell cycle and CDK2 has
been identified as the kinase system involved in cell cycle-regulated
phosphorylation of Ser38. Besides, three distinct protein kinases
have been identified to phosphorylate stathmin in response to
external signals. These kinases are members of the MAPK family
that phosphorylates Ser25, cyclic AMP-dependent protein kinase
(PKA) that phosphorylates Ser63 and CamKII that phosphory-
lates Ser16 [26]. Because the kinases acting at these residues are
distinct and may be functioning through different pathways, it is
reasonable to speculate that regulation of stathmin phosphoryla-
tion can be achieved by multiple pathways, thus providing the cell
with a finely tunable mechanism for controlling microtubule
assembly and dynamics in relation to its needs.
In the present study, the role of stathmin and its phosphory-
lation in bortezomib-induced cell death was further investigated by
overexpression of the WT stathmin and phosphorylation site-
deficient stathmin mutants S16A, S25A or S38A in myeloma cells.
Overexpression of WT stathmin significantly increased bortezo-
mib-induced cell death. On the contrary, overexpression of the
phosphorylation site-deficient stathmin mutants S16A, S25A and
S38A significantly decreased, but did not block, bortezomib-
induced cell death. Importantly, increased levels of tubulin
polymerization were observed upon bortezomib treatment in cells
overexpressing WT or mutant stathmin, but to a lesser extent than
parental U266 cells (Fig. 5C, Table 1). There are several possible
explanations as to why bortezomib-induced cell death is not
completely blocked by the stathmin mutants. First, endogenous
WT stathmin is still present, and thus the mutant protein has to
compete with the WT protein. Second, bortezomib can also
modulate the activity of other MT regulatory proteins that may
also contribute to the cell death [29] . Furthermore, the MT
system is not the only event involved in bortezomib-induced cell
death in myeloma cells [22,31]. This suggests that bortezomib-
induced cell death is the result of a concerted series of events.
Therefore, we conclude that bortezomib-induced phosphoryla-
tion of stathmin promotes cell death and that phosphorylation on
Ser16, Ser25 and Ser38 is necessary for this process. Furthermore,
the bortezomib-induced changes in the MT stabilization can be
attributed to the bortezomib-induced phosphorylation of stathmin,
and MT stabilization is in fact responsible for the bortezomib-
induced cell death-promoting activity of phosphorylated stathmin.
Another protein of interest uncovered in this study is BCL2-
associated athanogene 3 (BAG3). In the current study, BAG3 was
found to have increased phosphorylation at Ser377 upon
bortezomib treatment. BAG3 belongs to the evolutionarily
conserved BAG family of proteins that were originally isolated
based on their ability to interact with the anti-apoptotic protein
Bcl-2 [35,36]. It is involved in a wide variety of cellular processes,
including cell survival, cellular stress response, apoptosis and virus
replication [16,37,38]. Recent evidence implicates an additional
function of BAG3 in the regulation of the autophagy pathway.
These findings indicate that autophagosome formation and
turnover may depend on BAG3 and that BAG3 can stimulate
autophagy processes [39,40]. Autophagy is a major intracellular
degradation system. Unlike the ubiquitin-proteasome system
(UPS), autophagy is mainly responsible for the degradation of
long-lived proteins and subcellular organelles [41,42]. Autophagy
plays important roles in development, cellular homeostasis and cell
survival and is frequently activated in tumor cells exposed to
chemotherapy or radiation and confers therapeutic resistance
[43,44]. The UPS and autophagy have been viewed as distinct
degradation systems, but recent studies suggested that they are
functionally coupled and that suppression of the proteasome
promotes autophagy [45,46]. However, the functional connection
and the inter-regulation between the two systems are not well
understood.
Importantly, Zhu et al. has shown that proteasome inhibition
activates autophagy through a phosphorylation of eIF2a-depen-
dent mechanism to eliminate protein aggregates and alleviate
proteotoxic stress [46]. However, their results also demonstrated
that complicated mechanisms are involved in proteasome
inhibition-mediated autophagy activation and the phosphorylation
of eIF2a only partially accounts for this activation [46]. Thus, it is
possible that the complexity of the process may be much higher
than presently envisaged, and that other proteins may be as
important in controlling autophagy activation as eIF2a.
Based on the critical role of BAG3 in the stimulation of the
autophagy pathway, it is tempting to suggest that bortezomib-
induced phosphorylation of BAG3 might play an important role in
autophagy activation. Therefore, the increase in BAG3 phosphor-
Phosphoproteomics of Myeloma
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and appears to represent a novel mechanism with a link between
the two protein degradation systems. This speculative idea,
however, is not yet supported by the current experimental data,
and further investigations are undergoing to determine the
functional implication of BAG3 in coordination between the
proteasome and autophagy.
In summary, we have, for the first time, performed quantitative
phosphoproteomics to study the effects of bortezomib on MM
cells. The current results expand the list of bortezomib-targeted
phosphoproteins and their phosphorylation sites. Especially, our
functional studies indicated that bortezomib-induced phosphory-
lation of stathmin promotes cell death and that the bortezomib-
induced changes in the MT stabilization can be attributed to the
bortezomib-induced phosphorylation of stathmin. Our compre-
hensive study of phosphorylation regulation in proteasome
inhibition in MM cells may serve as a valuable resource for future
research in the field and thus advance the general mechanistic
understanding of bortezomib in MM.
Materials and Methods
Cell Culture and Metabolic Labeling
The human myeloma cell line U266 was purchased from
American Type Culture Collections (Rockville, MD). Myeloma
cells were routinely maintained in RPMI 1640 supplemented with
1% penicillin/streptomycin, 1 mmol/L L-glutamine, and 10%
fetal bovine serum at 37uC, 5% CO2 in air. Bortezomib was
provided by Millennium Pharmaceuticals (Cambridge, MA). To
differentially label bortezomib-treated and -untreated U266 cells,
the SILAC Protein Quantitation Kit (Pierce Biotechnology,
Rockford, USA) was used according to the manufacturer’s
instruction. In brief, cells were grown in SILAC RPMI 1640
Medium (Pierce Biotechnology, Rockford, USA) containing 10%
v/v dialyzed FBS, and either 0.1 mg/mL heavy [
13C6] or light
[
12C6] L-lysine (Pierce Biotechnology, Rockford, USA). To ensure
full incorporation of the heavy and light labeled amino acids, cells
were grown for at least six cell doublings prior to analysis. U266
cells were treated with 3 nM bortezomib for 24 h, according to the
half-maximal inhibitory concentration (IC50) measured by Hide-
shima et al [11]. After treatment, cells were washed three times
with ice-cold washing buffer (10 mM Tris–HCl, 250 mM sucrose,
pH 7.0) and transferred to a clean 1.5 mL Eppendorf tube. Cells
were lysed with RIPA lysis buffer (50 mM Tris-HCl, 150 mM
NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM
PMSF, 100 mM leupeptin, and 2 mg/mL aprotinin, pH 8.0).
Cellular debris was removed by centrifugation for 30 min at 13,
200 g and at 4uC. Protein concentrations were measured in
duplicate using RC DC protein assay (BioRad, Hercules, CA,
USA) and confirmed by SDS-PAGE.
Phosphopeptide Enrichment using TiO2
Phosphopeptide enrichment was performed as previously
described [17]. Briefly, equal amounts of proteins from untreated
(
13C6-lysine) and bortezomib-treated (
12C6-lysine) U266 cells were
mixed (1 mg in total) and subjected to disulfide reduction with
10 mM DTT (37uC, 3 h) and alkylation with 20 mM iodoaceta-
mide (room temperature, 1 h in dark). The protein mixtures were
mixed with four volumes of ice-cold acetone to precipitate
proteins. Precipitated proteins were collected by centrifugation
and washed with ethanol two times. The pellet was re-dissolved in
50 mM ammonium bicarbonate and then digested with sequenc-
ing grade modified trypsin (1:25 w/w) (Promega, Madison, WI) at
37uC for 20 h and then quenched by addition of TFA to a final
concentration of 0.5%. The digests were evaporated to about
20 mL in SpeedVac centrifuge. The phosphopeptides from
digested peptides were enriched by using Phosphopeptide
Enrichment TiO2 Kit (Calbiochem, San Diego, CA) according
to the manufacturer’s instruction with slight modifications. Briefly,
the tryptic digest was dried, re-dissolved in 200 mL TiO2
Phosphobind buffer containing 50 g/L 2,5-dihydroxybenzoic acid
and then mixed with 50 mL TiO2 Phosphobind Resin. After
30 min incubation, the supernatant was discarded, and TiO2 was
washed three times with the wash buffer. After that, 30 mL elution
buffer was added two times to elute the phosphopeptides. The
elutions were combined and acidified with 5 mL of 10% formic
acid for SCX-LC–MS/MS analysis. All the buffers and the
phosphopeptides purification resin were provided in the kit by the
manufacturer.
Peptide Analysis by LC-MS/MS Approach
The enriched phosphopeptides were analyzed with a Finnigan
Surveyor HPLC system coupled online with a LTQ-Oribitrap XL
(Thermo Fisher Scientific, Waltham, MA) equipped with a
nanospray source. The phosphopeptides were firstly loaded on a
strong cation exchange (SCX) column using an autosampler, and
the peptides were eluted by NH4Cl with different concentrations
(1 mM, 10 mM, 100 mM, 200 mM, 1 M). Then, each fraction
peptide was respectively loaded onto a C18 column (100 mm i.d.,
10 cm long, 5 mm resin from Michrom Bioresources, Auburn, CA)
using an autosampler. Peptides were eluted during a 0–35%
gradient (Buffer A, 0.1% formic acid, and 5% ACN; Buffer B,
0.1% formic acid and 95% AcN) over 90 min and online detected
in LTQ-Orbitrap using a data-dependent method [47]. The
general mass spectrometric conditions were: spray voltage, 1.80
kV; no sheath and auxiliary gas flow; ion transfer tube
temperature, 200uC. Ion selection thresholds were: 1000 counts
for MS
2 and 500 counts for MS
3. An activation q=0.25 and
activation time of 30 ms were applied in MS
2 acquisitions. The
mass spectrometers were operated in positive ion mode, employing
a data-dependent automatic switch between MS and MS
2
acquisition modes. For each cycle, one full MS scan in the
Orbitrap at 1610
6 AGC target was followed by five MS
2 in the
LTQ at 5000 AGC target on the five most intense ions. Selected
ions were excluded from further selection for 90 s. Maximum ion
accumulation time was 500 ms for full MS scans and 100 ms for
MS
2 scans. All MS/MS spectra were collected using normalized
collision energy (a setting of 35%), an isolation window of 3 m/z,
and 1 micro-scan. The resolution used in the MS step in the
Orbitrap is 60000. An extra DDNL (data-dependent neutral loss)
MS
3 method was applied for phosphopeptide detection [17]. MS
3
was triggered if a neutral loss peak at 298.0, 249.0, 232.7 or
224.5 Da was observed in the MS
2 and that peak was one of the
three most intense ions of the MS
2 spectra. Application of mass
spectrometer scan functions and HPLC solvent gradients were
controlled by XCalibur data system (Thermo Fisher Scientific,
Waltham, MA).
Phosphopeptide Identification, Validation and
Quantification
Peak lists for the database search were produced in the Mascot
generic format using BioWorks 3.3.1 (Thermo Finnigan, San Jose,
CA) and DTASuperCharge V 1.31 (SourceForge), and the derived
peak lists were searched using the Mascot 2.2.04 search engine
(Matrix Science, London, UK) against a real and false IPI human
database (V3.56, including 153, 078 protein entries). The
following search criteria were employed: full tryptic specificity
was required; two missed cleavages were allowed; Carbamido-
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Phospho (ST), and Phospho (Y) were considered as variable
modifications. Precursor ion mass tolerances were 10 ppm for all
MS acquired in the Orbitrap mass analyzer, fragment ion mass
tolerance was 0.5 Da for all MS
2 spectra acquired in the LTQ.
Mass spectra of identified phosphopeptides with peptide score
.10 were further processed and validated with the MSQuant 1.5
software for post-translational modification (PTM) score analysis
[48]. Two filters criteria for phosphopeptide identification were
applied: 1) Peptide score threshold was 17; 2) The total threshold
of PTM score and peptide score was 36. All fragmentation spectra
were manually verified using the criteria as described by Mann
et al [48]. For phosphopeptides with multiple potential phosphor-
ylation sites, the probabilities for phosphorylation at each site were
calculated from the PTM scores as described [48]. Phosphoryla-
tion sites that were occupied with probability .0.75 were reported
as class I phosphorylation sites. For class II sites, localization
probability was between 0.75 and 0.25. Phosphorylation sites with
localization probability ,0.25 were discarded. The identified
phosphopeptides were further processed with MSQuant 1.5 for
statistics evaluation as well as quantization.
Bioinformatics Analysis
Differentially expressed phosphoproteins (DEPPs) were classi-
fied based on the PANTHER (Protein ANalysis THrough
Evolutionary Relationships) system (http://www.pantherdb.org),
which is a unique resource that classifies genes and proteins by
their functions [49]. The DEPP interaction network was build
automatically by the STRING (Search Tool for the Retrieval of
Interacting Genes/Proteins) system with default setting except that
organism, confidence(score), and additional (white) nodes were set
to ‘‘human’’, ‘‘0.20’’, and ‘‘10’’, respectively[50,51]. The gene
name list of these proteins was input to search against the database
which contains known and predicted protein-protein interactions.
The retrieve included a detailed network which highlights several
hub proteins. The identified phosphoproteins were compared to
the public database of PhosphoSite (http://www.phosphosite.org/)
to find out the novel phosphoproteins and phosphosites. Each
confirmed phosphoprotein was searched with SCANSITE (http://
scansite.mit.edu) [52] forpotential kinasemotifswithhigh, medium,
and low stringency.
Western Blot Analysis
Protein extracts (30 mg) prepared with RIPA lysis buffer
(50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5%
sodium deoxycholate, 1 mM PMSF, 100 mM leupeptin, and
2 mg/mL aprotinin, pH 8.0) were resolved by a 10% SDS-PAGE
gel, and transferred onto Immobilon-P PVDF transfer mem-
braneS (Millipore, Bedford, MA) by electroblotting. After blocking
with 5% non-fat milk, the membranes were probed with rabbit
anti-CaMKII polyclonal, rabbit anti-phospho-CaMKII (Thr286)
polyclonal, goat anti-actin polyclonal antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit anti-CDK2 polyclonal,
rabbit anti-phospho-CDK2 (Thr160) polyclonal, rabbit anti-
phospho-stathmin (Ser25) polyclonal antibodies (Abcam Inc.,
Cambridge, MA), rabbit anti-His-tag polyclonal, rabbit anti-
stathmin polyclonal, rabbit anti-phospho-stathmin (Ser38) poly-
clonal, rabbit anti-phospho-stathmin (Ser16) polyclonal, rabbit
anti-p44/42 MAPK polyclonal, mouse anti-phospho-p44/42
MAPK (Thr202/Tyr204) monoclonal antibodies (Cell Signaling,
Danvers, MA), and mouse anti a-tubulin monoclonal antibodies
(DM1A, Sigma, St. Louis, MO). Blots were then incubated with
peroxidase-conjugated anti-mouse, anti-rabbit or anti-goat IgG
(KPL, Gaithersburg, Maryland) for 1 h at room temperature at a
1:2000 dilution and then developed by using the SuperSignal West
Pico Kit (Pierce Biotechnology, Rockford, IL).
Generation of Stathmin Mutants
Human stathmin was cloned into the NH2 terminal His-tagged
pReceiver-M01 expression vector (Genecopoeia, Rockville, MD).
Construction of mutant stathmin cDNAs, where the codons for
Ser-16, Ser-25 or Ser-38 are exchanged to Ala, was performed by
site-directed mutagenesis using a QuikChange kit (Stratagene, La
Jolla, CA) following the manufacturer’s instructions. Primers used,
with the introduced mutations underlined, were: (Ser16RAla) 59-
AGCGTGCCGCAGGCCAG-39; (Ser25RAla) 59-GCTGATT-
CTCGCCCCTCGGTC-39; (Ser38RAla) 59-CCCCCTTGCC-
CCTCCAAAG-39. All mutant constructs were confirmed by
DNA sequence analysis.
Establishment of Stable Transfectants
The plasmids were introduced in t oU 2 6 6c e l l su s i n gt h eX 0 0 5
mode of Nucleofector (Amaxa, Cologne, Germany), according to
the Optimized Protocol for the U266B1 cell line. Electroporated
cells were cultured in medium with the presence of 0.5 mg/ml
G418 (Mediatech, Manassas, VA) for 14 days, and then cultured
in the 96-well plates for dilution cloning. Finally, the clone
selected from pReceiver-M01 blank vector transfected U266
cells was designated as U266-NC. The clones selected from wild
type or mutant stathmin plasmids transfected U266 cells were
designated as U266-WT, U266-S16A, U266-S25A or U266-
S38A, respectively.
Assessment of Apoptosis
The extent of apoptosis was evaluated by using Annexin V/PI
staining and flow cytometry as described previously [53]. In brief,
1610
6 cells were washed once in 16PBS and were stained with
Annexin V-FITC and PI (2 mg/mL) according to manufacturer’s
instructions. Samples were acquired on a FACScan flow cytometer
(Becton Dickinson, San Jose, CA) and analyzed with the WinMDI
2.8 software program.
Tubulin Polymerization Assay
Tubulin polymerization assay was performed essentially as
previously described [29,54]. Briefly, cells grown to confluency in
24-well plates were washed twice with 1X PBS. To separate
polymerized (P) from soluble (S) tubulin, the cells were all
incubated at 37uC for 5 min in the dark in hypotonic lysis buffer
containing 5 mM paclitaxel, 10 mM Trichostatin-A (Calbiochem,
San Diego, CA), 1 mM MgCl2, 2 mM EGTA, 0.5% Nonidet P-
40, 2 mM phenylmethylsulfonyl fluoride, 200 units/ml aprotinin,
100 mg/ml soybean trypsin inhibitor, 5.0 mM e-amino caproic
acid, 1 mM benzamidine, and 20 mM Tris-HCl, pH 6.8,
vortexed vigorously and centrifuged at ,15,000 g at 22uC for
10 minutes. The supernatants containing soluble ‘S’ tubulin were
transferred to another Eppendorf tube separating them from the
pellets containing polymerized ‘P’ tubulin. Upon separation, tubes
were placed on ice and pellets of polymerized ‘P’ tubulin were
resuspended by sonication for 10-20 seconds in a volume of lysis
buffer equal to the soluble ‘S’ fraction. Each had gel sample buffer
added, equal aliquots were separated by 10% SDS-PAGE, and
western blots using anti-a-tubulin antibody were obtained. The
immunoblots were scanned, and densitometric analysis was
performed using the public domain NIH Image program ImageJ
(available on the Internet at http://rsb.info.nih.gov/nih-image/).
The percentage of polymerized ‘P’ tubulin was determined by
dividing the densitometry value of polymerized ‘P’ tubulin by the
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‘S’ and polymerized ‘P’ tubulin). An advantage of this assay is that
the amount of total protein loaded for each sample is irrelevant
since the ‘P’ and ‘S’ fractions are equalized for each pair, and it is
the proportion of the polymerized to the soluble tubulin fraction
that is measured.
Statistical analysis
All data are expressed as mean 6 standard deviation. Statistical
significance was determined by Student’s t-test (two-tailed), while
the significance of the differences was determined using the two-
tailed Mann–Whitney test. Statistical significance was assigned if
P,0.05.
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